End­points Man­u­fac­tur­ing: Lon­za drops in­gre­di­ents biz in $4.7B sale; Touch­light's 'dog­gy­boneD­NA' looks to rewrite rules of ther­a­peu­tic DNA

In a CD­MO in­dus­try flush with cash from Covid-19, the rich keep get­ting rich­er — but that doesn’t mean the top dogs aren’t look­ing for op­por­tu­ni­ties to of­fload lag­gard busi­ness­es and rake in some cash. That’s ex­act­ly what Lon­za did in hiv­ing off its in­gre­di­ents unit — End­points Man­u­fac­tur­ing’s top sto­ry of the week.

On Mon­day, the near­ly 125-year-old Swiss gi­ant di­vest­ed its spe­cial­ty in­gre­di­ents busi­ness in a $4.7 bil­lion deal with Bain Cap­i­tal and Cin­ven, the UK pri­vate eq­ui­ty firm. The sale will see Bain and Cin­ven take over Lon­za’s 17 in­gre­di­ents sites around the world, which host some 2,800 work­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER